Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

A. Pardanani, J. Gotlib, A. W. Roberts, M. Wadleigh, S. Sirhan, J. Kawashima, J. A. Maltzman, L. Shao, V. Gupta, A. Tefferi

Research output: Contribution to journalLetterpeer-review

13 Scopus citations
Original languageEnglish (US)
Pages (from-to)1034-1037
Number of pages4
Issue number4
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this